A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
- Determine the clinical effects of paricalcitol in patients with myelodysplastic
- Determine whether this drug can improve RBC, WBC, or platelet counts in these patients.
- Determine whether this drug can decrease the risk of development of leukemia without
causing undue toxicity in these patients.
OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease
progression or unacceptable toxicity.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
Masking: Open Label, Primary Purpose: Treatment
H. Phillip Koeffler, MD
Cedars-Sinai Medical Center
United States: Federal Government
|Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center||Los Angeles, California 90048|